


**What is claimed is:**

1. A topical ophthalmic, otic or nasal pharmaceutical composition comprising an antimicrobial effective amount of one or more compounds of the formula:

(I)



wherein:


A is CH, CF, CCl, C-OCH<sub>3</sub>, or N;

X<sup>1</sup> is H, halogen, NH<sub>2</sub>, or CH<sub>3</sub>;

R<sup>1</sup> is C<sub>1</sub> to C<sub>3</sub> alkyl, FCH<sub>2</sub>CH<sub>2</sub>, cyclopropyl or phenyl, optionally mono-, di- or tri-substituted by halogen, or A and R<sub>1</sub> together can form a bridge of formula C-O-CH<sub>2</sub>-CH(CH<sub>3</sub>);

R<sup>2</sup> is H, C<sub>1</sub> to C<sub>3</sub> alkyl (optionally substituted by OH, halogen or NH<sub>2</sub>), or 5-methyl-2-oxo-1,3-dioxol-4-yl-methyl; and

B is selected from the group consisting of:



wherein:

Y is O or CH<sub>2</sub>;

R<sup>3</sup> is C<sub>2</sub>-C<sub>5</sub> alkoxy, CH<sub>2</sub>-CO-C<sub>6</sub>H<sub>5</sub>, CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>R', R'O<sub>2</sub>C-CH=C-CO<sub>2</sub>R', CH=CH-CO<sub>2</sub>R' or CH<sub>2</sub>CH<sub>2</sub>-CN,

wherein:

R' is H or C<sub>1</sub> to C<sub>3</sub> alkyl;

R<sup>4</sup> is H, C<sub>1</sub> to C<sub>3</sub> alkyl, C<sub>2</sub>-C<sub>5</sub> alkoxy, CH<sub>2</sub>-CO-C<sub>6</sub>H<sub>5</sub>, CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>R', R'O<sub>2</sub>C-CH=C-CO<sub>2</sub>R', CH=CH-CO<sub>2</sub>R', CH<sub>2</sub>CH<sub>2</sub>-CN or 5-methyl-2-oxo-1,3-dioxol-4-yl-methyl,

wherein:

R' is H or C<sub>1</sub> to C<sub>3</sub> alkyl; and

their pharmaceutically useful hydrates and salts; and a pharmaceutically acceptable vehicle therefor.

2. A topical composition according to Claim 1, wherein the composition further comprises an anti-inflammatory effective amount of a steroidal or non-steroidal anti-inflammatory agent.

3. A topical composition according to Claim 2, wherein the anti-inflammatory agent comprises a glucocorticoid.

4. A topical composition according to Claim 3, wherein the glucocorticoid is selected from the group consisting of dexamethasone, rimexolone, prednisolone, fluorometholone, hydrocortisone, mometasone, fluticasone, beclomethasone, flunisolide, triamcinolone and budesonide.

5. A topical composition according to Claim 2, wherein the anti-inflammatory agent comprises a non-steroidal agent selected from the group consisting of prostaglandin H synthetase inhibitors, PAF antagonists, and PDE IV inhibitors.

6. A topical composition according to Claim 2, wherein the compound of formula (I) comprises moxifloxacin.

5 7. A topical composition according to Claim 6, wherein the anti-inflammatory agent comprises dexamethasone.

8. A method of treating or preventing ophthalmic, otic or nasal infections, which comprises topically applying a therapeutically effective amount of the composition of  
10 Claim 1 to the affected ophthalmic, otic or nasal tissue.

9. A method of treating or preventing ophthalmic, otic or nasal infections and attendant inflammation, which comprises topically applying a therapeutically effective amount of the composition of Claim 2 to the affected ophthalmic, otic or nasal tissue.

15

10. A method of treating or preventing ophthalmic, otic or nasal infections and attendant inflammation, which comprises topically applying a therapeutically effective amount of the composition of Claim 6 to the affected ophthalmic, otic or nasal tissue.